Transaction DateRecipientSharesTypePriceValue
10th September 2020Jennifer K. Simpson1,000Open or private purchase$2.74$2,737.10
1st September 2020Jennifer K. Simpson2,424Open or private purchase$0.00
8th May 2020Marco Taglietti6,000Conversion of derivative$0.00
8th May 2020Barbra Keck6,800Conversion of derivative$0.00
8th May 2020John Purpura6,500Conversion of derivative$0.00
8th May 2020Roger G Phd Stoll9,300Conversion of derivative$0.00
8th May 2020William Dodge Rueckert6,000Conversion of derivative$0.00
8th May 2020Jennifer K. Simpson14,700Conversion of derivative$0.00
6th May 2020Barbra Keck6,040Grant/award etc.$0.00
6th May 2020John Purpura6,613Grant/award etc.$0.00
Delcath Systems
Delcath Systems logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.

Delcath Systems, Inc. is an oncology company, which focuses on the treatment of primary and metastatic liver cancers. It develops and commercializes CHEMOSAT and Melphalan Hydrochloride for Injection.

Ticker: DCTH
Sector: Health Technology
Industry: Medical Specialties
SEC Central Index Key (CIK): 872912
Employees: 33
Exchange: NASDAQ
Auditor Opinion:Going Concern

Disclosure Language changes
Red Flags